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Abstract
Background: The objective of this study is to perform a meta-analysis to evaluate the associations between the
BRAFV600E mutation status and aggressive clinicopathological features and poor prognostic factors in papillary
thyroid cancer.
Methods: A literature search was performed within the PubMed, MEDLINE, Web of Science databases, and EMBASE
databases using the Medical Subject Headings and keywords from January 2003 to July 2015. Individual study-
specific odds ratios and confidence intervals were calculated, as were the Mantel-Haenszel pooled odds ratios for
the combined studies.
Results: Sixty-three studies of 20,764 patients were included in the final analysis. Compared with wild-type BRAF,
the BRAFV600E mutation was associated with aggressive clinicopathological factors, including extrathyroidal
extension, higher TNM stage, lymph node metastasis, and recurrence, and was associated with reduced overall
survival; however, there was no significant association between the presence of BRAF mutation and distant
metastasis.
Conclusions: BRAF mutations are closely associated with aggressive clinicopathological characteristics and poorer
prognosis in papillary thyroid cancer. Accordingly, aggressive treatment should be considered for papillary thyroid
cancer patients with BRAF mutation.
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Background
Papillary thyroid carcinoma (PTC) is the most common
malignant thyroid neoplasm, accounting for 80 % of all
thyroid cancers [1]. The incidence of PTC has increased
dramatically in the past decades [2], and Chen et al.
demonstrated that the increasing rate of PTC resulted
from an actual increase in disease incidence rather than
improvements in the diagnosis such as by high-resolution
ultrasound [3]. PTCs, especially papillary thyroid micro-
carcinomas, tend to have a good prognosis; however, even
for TNM stage I patients, approximately 15 % of patients
experienced recurrence during 10 years of follow-up in
one previous study [4]. Therefore, the classification and
targeted therapies for PTC still need more investigation.
The BRAFV600E mutation is a common mutation in
PTC, with a reported frequency of 25–82.3 %. Many
authors have reported that the BRAFV600E mutation is
associated with aggressive clinical features and poor
prognosis; however, others have suggested that there is
no association between the BRAFV600E mutation and
clinicopathologic features in PTCs [5–7]. Thus, it
remains controversial whether the BRAFV600E mutation
closely correlates with poor clinical characteristics in
PTC, and it is necessary to confirm the association
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between BRAFV600E and the clinical prognosis of PTC
using meta-analysis.
Accordingly, the present meta-analysis was designed
to determine whether the BRAFV600E mutation is associ-
ated with high-risk clinicopathological factors and poor
prognostic outcomes in PTC patients. Additionally, we
performed subgroup analyses to assess the effects of fac-
tors that might modify these associations. The results of
our meta-analysis are considered very helpful for clinical
surgeons to choose the optimal surgical managements,
such as whether prophylactic central neck dissection is
needed, and for postoperative risk stratification of PTCs.
Methods
A comprehensive search was conducted in the PubMed,
MEDLINE, and Web of Science databases from January
2003 to July 2015. The search terms and keywords used
included “papillary thyroid carcinoma,” “BRAF,” “muta-
tion,” “V600E,” “T1799A,” and “PTC.” All studies that
included BRAFV600E mutation data from primary PTC
tissues were further evaluated. In addition, the reference
lists from single case reports and relevant reviews arti-
cles were also inspected for further eligible studies by
two independent reviewers. Clinical characteristics such
as extrathyroidal invasion, lymph node metastasis, TNM
stage, cancer recurrence, and rates of cancer-specific
death at the last follow-up were included in the present
analysis. The search was restricted to English language
publications only. Duplicate articles and studies with no
clinicopathologic data were excluded. To avoid false-
negative results, studies that determined the BRAFV600E
mutation status by preoperative fine needle aspiration
biopsies only were also excluded. Further, studies con-
fined to only low-risk groups or papillary thyroid micro-
carcinomas were excluded, as were unpublished data
that were presented at international meetings. In in-
stances where the same study cohort was used in mul-
tiple articles, either the most recent or the most
appropriately informative single article was included. For
example, Fugazzola et al. [6] included only data from a
single institute and contained a cohort overlapping with
Fugazzola et al. [8]; therefore, we used the latter study
for our analysis.
Data analyses and statistical methods
We used RevMan (version 5) to calculate the summary
odds ratios (ORs) with 95 % confidence intervals (CIs),
using a random-effects model when p value (chi-square
test of homogeneity) <0.1 and a fixed-effects model
when p value (chi-square test of homogeneity) ≥0.1. We
assessed the heterogeneity of the studies using the chi-
square test of heterogeneity and the I2 measure of incon-
sistency. Significant heterogeneity was defined as a chi-
square test p value of <0.10 or as an I2 measure >50 %
(according to a statement from Cochrane Handbook).
The extent to which the combined metarisk or hetero-
geneity were affected by individual studies was assessed
further by sequentially excluding every study from the
meta-analysis. We investigated potential sources of the
identified heterogeneity among the studies using a strati-
fication process according to the country or ethnics in
which the research was conducted. The potential for
publication bias was assessed using a funnel plot
analysis.
Results
Results of the literature search and study characteristics
Figure 1 shows the study selection process. A total of
997 abstracts and titles of full-text papers obtained
through electronic searches were deemed relevant and
examined in detail. Following this detailed review, 63
studies met our inclusion/exclusion criteria; these stud-
ies contributed 20,764 patients with PTC to this meta-
analysis [6, 8–69]. The main features of the 63 eligible
studies that investigated prognostic factors are summa-
rized in Table 1. The funnel plots for each outcome did
not suggest the presence of publication bias (data not
shown).
Meta-analyses of BRAF mutation effects on
clinicopathological and prognostic features
BRAF mutation and extrathyroidal extension
Fifty-two studies contained data on extrathyroidal inva-
sion. Extrathyroidal invasion was present in 5306
(51.5 %) of 10,301 patients with BRAF mutations and in
1910 (28.7 %) of 6655 patients without BRAF mutations
(Fig. 2). The pooled odds ratio (OR) from these 52 stud-
ies was 2.04 (95 % confidence interval [CI], 1.75–2.37).
A random-effects model was adopted because the het-
erogeneity of the data was significant (p < 0.00001), and
the I2 estimate of the variance between the studies was
69 %. According to our analysis, the association between
the occurrence of extrathyroidal invasion and BRAF mu-
tation was significant (p < 0.00001).
BRAF mutation and TNM stage
TNM stage was reported for patients in 51 studies
(Fig. 3). The advanced TNM stage (III/IV) was present
in 2913 (37.5 %) of 7765 patients with BRAF mutations
and in 1364 (23.3 %) of 5842 patients without BRAF mu-
tations (Fig. 3). The pooled odds ratio (OR) from these
51 studies was 1.82 (95 % CI, 1.53–2.17). A random-
effects model was adopted because the heterogeneity of
the data was significant (p < 0.00001), and the I2 estimate
of the variance between the studies was 70 %. According
to our analysis, the association between the occurrence
of advanced TNM stage (III/IV) and BRAF mutations
was significant (p < 0.00001).
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BRAF mutation and lymph node metastasis
Lymph node metastasis was reported for patients in 51
studies (Fig. 4). Lymph node metastasis was present in
4575 (43.4 %) of 10,542 patients with BRAF mutations
and in 2405 (32.5 %) of 7394 patients without BRAF mu-
tations (Fig. 4). The pooled odds ratio (OR) from these
51 studies was 1.45 (95 % CI, 1.24–1.69). A random-
effects model was adopted because the heterogeneity of
the data was significant (p < 0.00001), and the I2 estimate
of the variance between the studies was 73 %. According
to our analysis, the association between the occurrence
of lymph node metastasis and BRAF mutations was sig-
nificant (p < 0.00001).
BRAF mutation and distant metastasis
Distant metastasis was reported for patients in 19 stud-
ies (Fig. 5). Distant metastasis was present in 77 (5.4 %)
of 1415 patients with BRAF mutations and in 98 (5.2 %)
of 1868 patients without BRAF mutations (Fig. 5). The
pooled odds ratio (OR) from these 19 studies was 1.05
(95 % CI, 0.65–1.68). A random-effects model was
adopted because the heterogeneity of the data was sig-
nificant (p = 0.05), and the I2 estimate of the variance be-
tween the studies was 37 %. According to our analysis,
the association between the occurrence of distant metas-
tasis and BRAF mutations was not significant (p = 0.85).
BRAF mutation and recurrence
Recurrence was reported in 24 studies (Fig. 6). Recur-
rence was present in 608 (24.8 %) of 2450 patients with
BRAF mutations and in 407 (14.1 %) of 2877 patients
without BRAF mutations (Fig. 6). The pooled OR from
these 24 studies was 2.20 (95 % CI, 1.57–3.09). A
random-effects model was adopted because the hetero-
geneity of the data was significant (p < 0.00001), and the
I2 estimate of the variance between the studies was 74 %.
According to our analysis, the association between the
occurrence of recurrence and BRAF mutations was sig-
nificant (p < 0.00001).
Fig. 1 The study selection process
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BRAF mutation and OS
Overall survival (OS) was reported in five studies (Fig. 7).
OS was present in 65 (5.1 %) of 1264 patients with
BRAF mutations and in 17 (1.1 %) of 1605 patients with-
out BRAF mutations (Fig. 7). The pooled OR from these
five studies was 4.61 (95 % CI, 2.69–7.90). A fixed-
effects model was adopted because the heterogeneity of
the data was not significant (p = 0.77), and the I2 esti-
mate of the variance between the studies was 0 %. Ac-
cording to our analysis, the association between the
occurrence of death and BRAF mutations was significant
(p = <0.00001).
Subgroup analyses of the BRAF mutation effects on
aggressive clinicopathological features and poor
prognostic factors
Subgroup analysis was conducted according to the eth-
nicities of the study subjects in order to investigate the
potential sources of heterogeneity and to assess whether
the effects of the BRAF mutation status on aggressive
clinicopathological features and poor prognosis of PTC
patients were associated with geographic regions
(Table 2). The heterogeneity was decreased in the sub-
group analyses of extrathyroidal invasion, TNM stage,
lymph node metastasis, and recurrence. Thus, the results
Table 1 Summary of the 63 included studies






O'Neill [26] A 85/22 79.4
Daliri [65] A 28/41 40.6
Han [51] A 353/146 70.7
HE [59] A 119/68 63.6
Namba [28] A 26/14 65.0
Ahn [27] A 38/88 30.2
Hong1 [61] A 120/73 62.2
Hong2 [61] A 1792/639 73.7
Liu [12] A 213/126 62.8
Jung [36] A 162/48 77.1
Kim [41] A 64/15 81.0
Kim [7, 43] A 34/69 33.0
Kim [7] A 149/54 73.4
Kim [66] A 265/57 82.3
LEE [16] A 58/42 42.0
Lee [9] A 24/40 37.5
Lim [54] A 2219/728 75.3
Liu [40] A 47/54 46.5
Liu [12] A 80/52 60.6
Rivera [42] A 43/18 70.5
Khan [56] A 15/45 25
Shao [58] A 133/67 66.5
Wang [57] A 80/35 69.6
Lee [16] A 241/390 38.4
Puxeddu [22] A 281/485 36.4
Yim [50] A 123/41 75
Jo [44] A 102/59 63.4
Zeng [62] A 465/154 75.1
Henke [67] A and C 340/168 66.9
Czarniecka [64] C 38/50 43.2
Abrosimov [34] C 23/17 57.5
Alzahrani [47] C 96/185 34.2
Guerra [48] C 90/78 53.6
Frasca [25] C 60/41 59.4
Ahn [27] C 217/286 45.4
Durante [20] C 56/37 60.2
Nikiforova [21] C 24/36 40.0
Frasca [25] C 125/198 38.7
Fugazzola [8] C 99/161 38.1
Basolo [32] C 472/575 45.1
Basolo [32] C 229/349 39.6
Oler [49] C 48/25 65.8
Howell [14] C 86/133 39.3
Table 1 Summary of the 63 included studies (Continued)
Nakayama [29] C 173/124 58.2
Fernandez [30] C 153/143 51.7
Fugazzola [6] C 18/29 38.3
Lee [69] C 44/19 70
Li [55] C 297/91 76.5
Yip [39] C 99/100 49.7
Jung [36] C 19/24 44.2
Durante [20] C 38/66 36.5
Howell [14] C 15/40 27.3
Pelizzo [35] C 98/43 69.5
McKelvie [68] C 45/22 67.2
Riesco [37] C 28/39 41.8
Ito [23] C 38/64 37.3
Russo [60] C 57/46 55.3
Ulisse [45] C 44/47 48.4
Sykorova [63] C 81/161 33.5
Musholt [46] C 122/168 42.1
Angell [53] C 16/17 48.9
Xing [18] C 107/112 48.9
Xing [19] C 73/117 40.6
Xing [52] C 194/313 38.3
Xing [1, 10] C/A 845/1004 45.7
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of the subgroup analyses indicated that the BRAF muta-
tion status may differ according to ethnicity.
Discussion
BRAFV600E was first described as a mutation related to
the MEK-ERK pathway in human cancer by Davies et al.
in 2002. Since then, the BRAFV600E mutation has been
reported as a biological marker for the aggressiveness
and prognosis of numerous cancers, including malig-
nant melanoma and thyroid cancer among others.
Among the three Raf isoforms, BRAF is the strongest
downstream activator of the MEK pathway. As a
downstream target of MEK, the phosphorylation of
ERK can activate substrates located in both the cyto-
plasm and nucleus. Abnormal activation of this path-
way, for example by BRAF mutation, results in the
disruption of biological homeostasis and may result in
tumor transformation [70, 71].
Since its initial discovery, the BRAFV600E mutation has
been debatable as a diagnostic as well as prognostic indi-
cator of PTC, as many of the studies on the topic have re-
ported contradictory outcomes of the association between
the BRAFV600E mutation and clinical characteristics and
Fig. 2 The odds ratios (ORs) with 95 % confidence intervals (CIs) for the association between BRAF mutation and extrathyroidal extension in
patients with PTC
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prognosis [37, 40]. Therefore, the present meta-analysis to
illustrate the role of BRAF mutation in PTC was consid-
ered highly necessary.
Various clinicopathological risk factors have been re-
ported to be related to recurrence and cancer death in
PTC [72]; according to most authors’ results, we chose
extrathyroidal invasion, lymph node metastasis, ad-
vanced TNM stage, and distant metastasis as reliable
predictors for poor prognosis in the present analysis, as
these factors not only represent aggressive cancer behav-
ior but also poor prognosis [72, 73].
Extrathyroidal extension is associated with an in-
creased risk of invasion into cervical structures such
as the trachea, which requires more aggressive treat-
ment. Accordingly, extrathyroidal extension is an im-
portant factor related to PTC prognosis, contributing
Fig. 3 The odds ratios (ORs) with 95 % confidence intervals (CIs) for the association between BRAF mutation and advanced TNM stage (III/IV) in
patients with PTC
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to an increased risk of local recurrence/persistence of
the disease, independent of the tumor size [74]. In
our meta-analysis, the risk of extrathyroidal extension
was increased by 2.04-fold in cases with positive
BRAF mutation status compared to in wild-type
cases. In fact, out of all included studies, only six
studies showed that patients with BRAF mutation
presented less frequent extrathyroidal extension than
those without BRAF mutation.
The American Joint Committee on Cancer (AJCC) sta-
ging system comprises the sum of several tumor charac-
teristics, such as the tumor size, lymph node status, and
distant metastasis, which are generally considered ag-
gressive features of cancer. AJCC stage III/IV cancers are
associated with a poorer prognosis in terms of both re-
currence and overall survival than stage I/II tumors [75].
According to our results, there was a significant associ-
ation between high AJCC stage and BRAF mutation,
Fig. 4 The odds ratios (ORs) with 95 % confidence intervals (CIs) for the association between BRAF mutation and lymph node metastasis in
patients with PTC
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with positive BRAF mutation status being associated
with a 1.82-fold increased risk of stage III/IV cancers
compared to wild-type cases. Out of all included studies,
nine studies suggested that the risk of a high AJCC stage
was lower in patients with BRAF mutation than in those
without BRAF mutation; however, the other 42 studies
demonstrated the opposite results, especially for patients
aged >45 years, in whom positive BRAF mutation status
was associated with more frequent cases of stage III/IV
cancers compared to stage I/II [20, 76]. Howell et al. also
reported that older age and positive mutation status
were more frequently associated with TNM stage III/IV
and recurrence [14].
Further, according to the present meta-analysis, the
prevalence of lymph node metastasis was increased in
patients with BRAF mutation, with an odds ratio of
1.45; increased risk was observed in 39 of 60 studies.
Lymph node metastasis is an important risk factor for
recurrence and/or persistent disease, as well as overall
survival [75]. Based on these results, we suggest that
the presence of BRAF mutation is a prognostic factor
in PTCs. However, it is worth mentioning that the
different surgical approaches and treatments used in
these 60 studies probably influenced the outcome in
terms of the real incidence of nodal metastasis; there-
fore, evaluation of the BRAF mutation status as a
prognostic indicator for lymph node metastasis in
PTCs should be more cautious [74].
Recurrence and persistent disease demand additional
therapy and can affect the PTC patients’ quality of life. For
example, recurrence increases the risk of reoperations and
the exposure to a high cumulative radioiodine dose. Re-
cently, Xing et al., in their large multicenter study, demon-
strated that the BRAFV600E mutation was an independent
prognostic factor for PTC recurrence in various clinico-
pathologic categories [77]. However, these outcomes were
questioned by Bal & Ballal and Yarchoan et al. [78, 79], as
the median follow-up was only 36 months and the recur-
rence rate was very high, which might have resulted from
persistent disease rather than true recurrence. However,
our meta-analysis indicated that the association between
the occurrence of recurrence and BRAF mutations was
significant, and these results were obtained from 24 stud-
ies including a total of 2450 patients; hence, our findings
are considered more reliable.
Our present meta-analysis encompassing a total of
20,764 patients suggested that the BRAFV600E mutation is
associated with several of the high-risk clinical variables
used in prognostic staging systems, including extrathyroi-
dal invasion, high TNM stage, lymph node metastasis,
recurrence, and overall survival. Especially, PTCs with
positive BRAFV600E mutation exhibited a 4.61-fold in-
creased risk of death compared with cases with the wild-
type form of the BRAF gene. On the other hand, one in-
teresting finding in the present meta-analysis was that the
BRAFV600E mutation was not related to distant metastasis.
Fig. 5 The odds ratios (ORs) with 95 % confidence intervals (CIs) for the association between BRAF mutation and distant metastasis in patients
with PTC
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One potential reason for this result may be the fact that
the diagnosis of distant metastasis differs between differ-
ent countries and medical centers.
There were several limitations regarding our study
design, especially in terms of the studies included in our
analysis. Additionally, our study could not determine a
causal relationship between BRAF mutations and out-
comes, and BRAF mutations may correlate with some
other mutations or confounders, which may turn out to
be even more useful prognostic indicators. Importantly,
our analysis should be interpreted with caution because
of the heterogeneity in the data. Possible explanations
for this heterogeneity include differences in the patient
demographics and ethnicities, as well as in the thyroid-
ectomy, approaches to lymph node dissection, pathology
reporting, radioactive iodine treatment, and the time of
follow-up. Therefore, our conclusions should be inter-
preted with caution.
Fig. 6 The odds ratios (ORs) with 95 % confidence intervals (CIs) for the association between BRAF mutation and recurrence with PTC
Fig. 7 The odds ratios (ORs) with 95 % confidence intervals (CIs) for the association between BRAF mutation and OS with PTC
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Conclusions
In conclusion, our meta-analysis illustrated that the
BRAFV600E mutation correlates with high-risk clinicopath-
ological factors and poor clinical outcome. These results
provide a valuable reference for physicians when assessing
the prognosis of PTCs by BRAFV600E mutation analysis,
and our findings may be of great value in evidence-based
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